<DOC>
	<DOCNO>NCT00088634</DOCNO>
	<brief_summary>A 6-week in-patient out-patient study test effectiveness safety new medication treatment schizophrenia</brief_summary>
	<brief_title>A Study Test Effectiveness Safety New Medication Treatment Schizophrenia</brief_title>
	<detailed_description>Study evaluate efficacy new compound versus placebo treatment patient schizophrenia ( diagnose DSM-IV criterion ) measure reduction baseline total score Brief Psychiatric Rating Scale ( BPRS ) extract Positive Negative Syndrome Scale ( PANSS ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Satisfy DSMIV criterion schizophrenia establish SCIDCV The patient must agree voluntary hospitalization duration 31 day minimum start treatment If female , must pregnant , must incapable conceive take step prevent conception The patient use investigational drug within past 30 day The patient participate previous study compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Latuda</keyword>
	<keyword>Lurasidone</keyword>
</DOC>